Symbiotec Pharmalab Board Meeting on Sep 21 to Approve Q1 FY27 Results

Symbiotec Pharmalab Ltd has announced that its Board of Directors will convene on September 21, 2026. The primary agenda item is the consideration and approval of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these results. Further details are available on the company's website.